GlassScriptPhysician profile
Kent J Covert
NPI 1568414415
$11,019.34
in general payments reported to CMS, 2019-2025
51 companies · $756 in 2025
The $756 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $1,776 · 2021: $2,099 · 2022: $2,161 · 2023: $1,581 · 2024: $1,209 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,452 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,452.35 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,226.05 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,074.62 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,031.37 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $839.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $736.03 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $689.23 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $578.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $472.79 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $448.22 | 2019-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Takeda Pharmaceuticals U.S.A., INC. | $395.82 | 2019-2023 | Trintellix |
| Pfizer INC. | $379.26 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.44 | 2019-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $248.19 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $221.88 | 2022 | |
| Allergan, INC. | $186.51 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Covert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.